Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Amicus initiated with a Buy at BTIG » 19:57
06/16/20
06/16
19:57
06/16/20
19:57
FOLD

Amicus

$13.08 /

+1.92 (+17.20%)

BTIG analyst Dae Gon Ha…

BTIG analyst Dae Gon Ha initiated coverage of Amicus with a Buy rating and $19 price target. The company's oral precision medicine Galafold continues to generate revenue growth worldwide across both enzyme replacement therapy-switchers and treatment-naive patients, the analyst tells investors in a research note, adding that the drug's success de-risks the company's proprietary chaperone advanced replacement therapy technology.

ShowHide Related Items >><<
FOLD Amicus
$13.08 /

+1.92 (+17.20%)

FOLD Amicus
$13.08 /

+1.92 (+17.20%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
06/08/20 JPMorgan
Amicus weakness 'overdone' following Sanofi update, says JPMorgan
05/18/20 JPMorgan
Amicus price target raised to $21 from $18 at JPMorgan
FOLD Amicus
$13.08 /

+1.92 (+17.20%)

Conference/Events
Amicus participates in a conference call with Cantor Fitzgerald » 12:25
06/16/20
06/16
12:25
06/16/20
12:25
FOLD

Amicus

$12.98 /

+1.82 (+16.31%)

Conference call with…

Conference call with management will be held on June 16 at 1 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
FOLD Amicus
$12.98 /

+1.82 (+16.31%)

FOLD Amicus
$12.98 /

+1.82 (+16.31%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
06/08/20 JPMorgan
Amicus weakness 'overdone' following Sanofi update, says JPMorgan
05/18/20 JPMorgan
Amicus price target raised to $21 from $18 at JPMorgan
FOLD Amicus
$12.98 /

+1.82 (+16.31%)

Recommendations
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright » 10:47
06/16/20
06/16
10:47
06/16/20
10:47
FOLD

Amicus

$13.58 /

+2.42 (+21.68%)

, SNY

Sanofi

$51.39 /

+0.82 (+1.62%)

After Sanofi (SNY)…

After Sanofi (SNY) reported data from its Phase 3 COMET study, which evaluated avalglucosidase alfa, or "NeoGAA," in enzyme replacement therapy naive late-onset Pompe disease patients, H.C. Wainwright analyst Debjit Chattopadhyay said the "overall picture emerging from" the COMET program has positive implications for the Amicus-sponsored PROPEL Phase 3 program. The analyst, who expects Amicus' AT-GAA to perform better than NeoGAA in switch patients, reiterates his Buy rating and $20 price target on Amicus (FOLD) shares.

ShowHide Related Items >><<
SNY Sanofi
$51.39 /

+0.82 (+1.62%)

FOLD Amicus
$13.58 /

+2.42 (+21.68%)

FOLD Amicus
$13.58 /

+2.42 (+21.68%)

06/08/20 JPMorgan
Amicus weakness 'overdone' following Sanofi update, says JPMorgan
05/18/20 JPMorgan
Amicus price target raised to $21 from $18 at JPMorgan
05/11/20 Janney Montgomery Scott
Amicus programs seem minimally affected by COVID, says Janney Montgomery Scott
SNY Sanofi
$51.39 /

+0.82 (+1.62%)

06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
SNY Sanofi
$51.39 /

+0.82 (+1.62%)

FOLD Amicus
$13.58 /

+2.42 (+21.68%)

SNY Sanofi
$51.39 /

+0.82 (+1.62%)

SNY Sanofi
$51.39 /

+0.82 (+1.62%)

SNY Sanofi
$51.39 /

+0.82 (+1.62%)

Conference/Events
Amicus participates in a conference call with Cantor Fitzgerald » 04:55
06/16/20
06/16
04:55
06/16/20
04:55
FOLD

Amicus

$11.16 /

+0.23 (+2.10%)

Conference call with…

Conference call with management will be held on June 16 at 1 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
FOLD Amicus
$11.16 /

+0.23 (+2.10%)

FOLD Amicus
$11.16 /

+0.23 (+2.10%)

06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
06/08/20 JPMorgan
Amicus weakness 'overdone' following Sanofi update, says JPMorgan
05/18/20 JPMorgan
Amicus price target raised to $21 from $18 at JPMorgan
05/11/20 Janney Montgomery Scott
Amicus programs seem minimally affected by COVID, says Janney Montgomery Scott
FOLD Amicus
$11.16 /

+0.23 (+2.10%)

Conference/Events
Amicus participates in a conference call with Cantor Fitzgerald » 16:10
06/11/20
06/11
16:10
06/11/20
16:10
FOLD

Amicus

$11.13 /

-0.68 (-5.76%)

Conference call with…

Conference call with management will be held on June 16 at 1 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
FOLD Amicus
$11.13 /

-0.68 (-5.76%)

FOLD Amicus
$11.13 /

-0.68 (-5.76%)

06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
06/08/20 JPMorgan
Amicus weakness 'overdone' following Sanofi update, says JPMorgan
05/18/20 JPMorgan
Amicus price target raised to $21 from $18 at JPMorgan
05/11/20 Janney Montgomery Scott
Amicus programs seem minimally affected by COVID, says Janney Montgomery Scott
FOLD Amicus
$11.13 /

-0.68 (-5.76%)

Recommendations
Amicus shares worth $10 on Galafold alone, says Citi » 06:41
06/09/20
06/09
06:41
06/09/20
06:41
FOLD

Amicus

$11.73 /

-1.17 (-9.07%)

, SNY

Sanofi

$50.75 /

+0.72 (+1.44%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal attributes the weakness yesterday in shares of Amicus Therapeutics (FOLD) to Sanofi's (SNY) press release indicating that the company will release Phase 3 data for avalglucosidase alfa at a virtual science session on June 16. This is a key event for Amicus as this neoGAA would compete with its investigational drug AT-GAA, Bansal tells investors in a research note. Given the company issued a press release about hosting such an event, investors are likely putting a high probability to neoGAA's success, hence the weakness in Amicus shares, says the analyst. However, he sees enough differences between the respective Phase 3 programs that it is not easy to compare neoGAA data with AT-GAA on an apples to apples basis. Further, Amicus does not get much credit for AT-GAA in current valuation as fair value of the company is $10 per share on Galafold alone, contends Bansal. The analyst keeps a Buy rating on the shares with a $15 price target.

ShowHide Related Items >><<
SNY Sanofi
$50.75 /

+0.72 (+1.44%)

FOLD Amicus
$11.73 /

-1.17 (-9.07%)

FOLD Amicus
$11.73 /

-1.17 (-9.07%)

06/08/20 JPMorgan
Amicus weakness 'overdone' following Sanofi update, says JPMorgan
05/18/20 JPMorgan
Amicus price target raised to $21 from $18 at JPMorgan
05/11/20 Janney Montgomery Scott
Amicus programs seem minimally affected by COVID, says Janney Montgomery Scott
04/07/20 JPMorgan
Amicus a top pick amid COVID-19 pandemic at JPMorgan
SNY Sanofi
$50.75 /

+0.72 (+1.44%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 UBS
Sanofi price target lowered to EUR 101 from EUR 103 at UBS
SNY Sanofi
$50.75 /

+0.72 (+1.44%)

FOLD Amicus
$11.73 /

-1.17 (-9.07%)

SNY Sanofi
$50.75 /

+0.72 (+1.44%)

SNY Sanofi
$50.75 /

+0.72 (+1.44%)

SNY Sanofi
$50.75 /

+0.72 (+1.44%)

Recommendations
Amicus weakness 'overdone' following Sanofi update, says JPMorgan » 15:15
06/08/20
06/08
15:15
06/08/20
15:15
FOLD

Amicus

$11.37 /

-1.53 (-11.86%)

, SNY

Sanofi

$50.72 /

+0.69 (+1.38%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama noted that shares of Amicus (FOLD) were under pressure today following the Sanofi (SNY) neoGAA Pompe update. The analyst believes the weakness in Amicus shares is "overdone," saying "we have known for some time that the neoGAA COMET data would be a Q2 event." Rama said that Amicus "continues to be a top idea... driven by commercial Galafold, AT-GAA Pompe program, and gene therapy optionality." The analyst reiterated an Overweight rating on Amicus shares.

ShowHide Related Items >><<
SNY Sanofi
$50.72 /

+0.69 (+1.38%)

FOLD Amicus
$11.37 /

-1.53 (-11.86%)

FOLD Amicus
$11.37 /

-1.53 (-11.86%)

05/18/20 JPMorgan
Amicus price target raised to $21 from $18 at JPMorgan
05/11/20 Janney Montgomery Scott
Amicus programs seem minimally affected by COVID, says Janney Montgomery Scott
04/07/20 JPMorgan
Amicus a top pick amid COVID-19 pandemic at JPMorgan
03/03/20 Baird
Amicus pipeline remains underappreciated, says Baird
SNY Sanofi
$50.72 /

+0.69 (+1.38%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 UBS
Sanofi price target lowered to EUR 101 from EUR 103 at UBS
05/26/20 Piper Sandler
Piper remains buyer of Regeneron, ups target to $630 on buyback accretion
SNY Sanofi
$50.72 /

+0.69 (+1.38%)

FOLD Amicus
$11.37 /

-1.53 (-11.86%)

SNY Sanofi
$50.72 /

+0.69 (+1.38%)

SNY Sanofi
$50.72 /

+0.69 (+1.38%)

SNY Sanofi
$50.72 /

+0.69 (+1.38%)

Over a month ago
Recommendations
Amicus price target raised to $21 from $18 at JPMorgan » 09:06
05/18/20
05/18
09:06
05/18/20
09:06
FOLD

Amicus

$11.60 /

+0.46 (+4.13%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama raised the firm's price target on Amicus to $21 from $18 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
FOLD Amicus
$11.60 /

+0.46 (+4.13%)

FOLD Amicus
$11.60 /

+0.46 (+4.13%)

05/11/20 Janney Montgomery Scott
Amicus programs seem minimally affected by COVID, says Janney Montgomery Scott
04/07/20 JPMorgan
Amicus a top pick amid COVID-19 pandemic at JPMorgan
03/03/20 Baird
Amicus pipeline remains underappreciated, says Baird
02/04/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
FOLD Amicus
$11.60 /

+0.46 (+4.13%)

Recommendations
Amicus programs seem minimally affected by COVID, says Janney Montgomery Scott » 08:01
05/11/20
05/11
08:01
05/11/20
08:01
FOLD

Amicus

$11.68 /

+0.08 (+0.69%)

Janney Montgomery Scott…

Janney Montgomery Scott analyst Yun Zhong reiterates Buy rating and $20 fair value estimate on Amicus shares following the company's Q1 update, which suggested only modest impacts on both Galafold's launch and the ongoing clinical programs due to COVID-19. Management reiterated its guidance on 2020 revenue and a top-line Pompe data readout in the first half of 2021, noted Zhong, who sees Amicus having a portfolio of assets at different stages from preclincal to commercial and strong long-term potential from its gene therapy pipeline.

ShowHide Related Items >><<
FOLD Amicus
$11.68 /

+0.08 (+0.69%)

04/07/20 JPMorgan
Amicus a top pick amid COVID-19 pandemic at JPMorgan
03/03/20 Baird
Amicus pipeline remains underappreciated, says Baird
02/04/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
10/14/19 H.C. Wainwright
Amicus recent selloff brings 'compelling opportunity,' says H.C. Wainwright
Hot Stocks
Amicus to hold Annual Meeting virtually » 07:23
05/08/20
05/08
07:23
05/08/20
07:23
FOLD

Amicus

$11.60 /

-0.22 (-1.86%)

Amicus Therapeutics…

Amicus Therapeutics announced that its 2020 Annual Meeting of Stockholders will now be held solely via live webcast due to the public health impact of the COVID-19 pandemic and out of an abundance of concern for the health and well-being of our employees, stockholders and directors. As previously announced, the 2020 Annual Meeting will be held on June 4, 2020 at 9:00 am ET.

ShowHide Related Items >><<
FOLD Amicus
$11.60 /

-0.22 (-1.86%)

04/07/20 JPMorgan
Amicus a top pick amid COVID-19 pandemic at JPMorgan
03/03/20 Baird
Amicus pipeline remains underappreciated, says Baird
02/04/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
10/14/19 H.C. Wainwright
Amicus recent selloff brings 'compelling opportunity,' says H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.